Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study
ConclusionsPatients treated with aflibercept or ranibizumab for different indications may be associated with varying risk of TAEs. The findings provide evidence to support treatment selection, taking indications and TAE risk into consideration.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Cardiology | Databases & Libraries | Diabetes | Drugs & Pharmacology | Endocrinology | Health Insurance | Heart | Heart Disease | Insurance | Ischemic Stroke | Lucentis | Pulmonary Thromboembolism | Ranibizumab Injection | Statistics | Stroke | Study | Taiwan Health | Thrombosis